COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (AMEX:CLN) today reported that Dr. Sergio Dromi (Research Fellow, Diagnostic Radiology Department, NIH Clinical Center, Bethesda, MD) will present data on Pulsed-High Intensity Focused Ultrasound (HIFU) enhanced delivery of tissue levels of doxorubicin and resultant tumor growth inhibition when using heat sensitive liposomes encapsulating doxorubicin (ThermoDox). The oral presentation will be on Monday, March 5th between 8-10 a.m. at the Annual Meeting of the Society of Interventional Radiology in Seattle, WA. The study was conducted under the leadership of Dr. Steven Libutti, (Surgery Branch, NCI) with Dr. Brad Wood, MD and Dr. Victor Frenkel, PhD (Diagnostic Radiology Department & Molecular Imaging Laboratory, NIH Clinical Center, Bethesda, MD).
